Merck & Co and AstraZeneca are to halt a Phase III study of cancer blockbusters Keytruda and Lynparza as a third-line treatment of metastatic castration-resistant prostate cancer (mCRPC) after the combination failed to show benefits to patients.
The result is a rare setback for Keytruda and Lynparza, which have grown steadily to lead their respective PD-1/PD-L1 and...



![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

